Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.
Journal: Therapeutic advances in rare disease
Published: March 28, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: February 17, 2025
Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease.
Journal: Frontiers in neurology
Published: December 05, 2024
Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.
Journal: Journal of neurology
Published: July 25, 2024
Switching Enzyme Replacement Therapy for Late-Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL.
Journal: Muscle & nerve
Published: June 27, 2024
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Journal: Journal of neurology
Published: October 23, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: August 17, 2023
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Journal: The Lancet. Neurology
Published: May 21, 2021
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.
Journal: The European respiratory journal
Published: February 09, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
Journal: The Journal of allergy and clinical immunology
Published: September 23, 2020
Benralizumab for the Prevention of COPD Exacerbations.
Journal: The New England journal of medicine
Published: May 22, 2019
Last Updated: 09/26/2026